AIKI AIkido Pharma
AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company's platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, we are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.
Company profile
Ticker
AIKI
Exchange
Website
CEO
Anthony Hayes
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
PPD • IQVIA • PRA Health Sciences • Charles River Laboratories International • Syneos Health • Icon • Medpace • Incyte • Zymergen • National Research ...
Former names
BIOSPHERICS INC, SPHERIX INC
SEC CIK
Corporate docs
IRS number
520849320
AIKI stock data
()
News
AIkido Pharma Announces Notice Of Allowance For U.S. Patent For Technology For Use Of 'ovel and proprietary central nervous system (CNS) homing peptides'
27 Jul 21
5 Value Stocks In The Healthcare Sector
26 Jul 21
5 Value Stocks In The Healthcare Sector
19 Jul 21
AIkido Pharma Issues Update On Antiviral Platform With The University Of Maryland
16 Jul 21
AIkido Pharma To Attend Alzheimer's Association International Conference
13 Jul 21
Press releases
Notice of Allowance Issued for Central Nervous System Peptide Technology
27 Jul 21
AIkido Pharma Issues Update on Antiviral Platform with the University of Maryland
16 Jul 21
AIkido Pharma to Attend the Alzheimer's Association International Conference
13 Jul 21
AIkido Pharma Files Patent Application for the Use of Ketamine to Treat Alzheimer's Disease
23 Jun 21
AIkido Pharma Announces Positive Phase 1 Data Presented at ASCO on 225Ac-J591
4 Jun 21
Investment data
Securities sold
Number of investors
Calendar
10 May 21
28 Jul 21
31 Dec 21
Financial summary
Quarter (USD) |
Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Annual (USD) |
Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Financial data from company earnings reports.
| Cash burn rate (estimated) | Burn method: Change in cash | Burn method: Operating income/loss | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 7.98M | 7.98M | 7.98M | 7.98M | 7.98M | 7.98M |
| Cash burn (monthly) | (positive/no burn) | (positive/no burn) | 772.67K | 538.75K | 351K | 302.17K |
| Cash used (since last report) | n/a | n/a | 3.02M | 2.11M | 1.37M | 1.18M |
| Cash remaining | n/a | n/a | 4.96M | 5.87M | 6.61M | 6.8M |
| Runway (months of cash) | n/a | n/a | 6.4 | 10.9 | 18.8 | 22.5 |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 3 May 21 | Hayes Anthony | Common Stock | Buy | Aquire P | No | No | 0.99 | 10,000 | 9.9K | 78,430 |
| 29 Apr 21 | Hayes Anthony | Common Stock | Buy | Aquire P | No | No | 0.99 | 10,000 | 9.9K | 68,430 |
| 22 Apr 21 | Hayes Anthony | Common Stock | Buy | Aquire P | No | No | 0.93 | 10,000 | 9.3K | 58,430 |
| 26 May 20 | AIkido Pharma | Common Stock | Sell | Dispose S | No | No | 1.25 | 400,000 | 500K | 1,130,674 |
Institutional ownership Q1 2021
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
13F holders |
Current |
|---|---|
| Total holders | 0 |
| Opened positions | 0 |
| Closed positions | 0 |
| Increased positions | 0 |
| Reduced positions | 0 |
13F shares |
Current |
|---|---|
| Total value | 0 |
| Total shares | 0 |
| Total puts | 0 |
| Total calls | 0 |
| Total put/call ratio | – |
Largest owners |
Shares | Value |
|---|
Financial report summary
?Management Discussion
- The Company experienced very little or no revenue in the last two years and we don’t expect any revenue until a biotechnology product is fully developed which may not occur for many years.
- For the year ended December 31, 2020 and 2019, we incurred a loss from operations of $6.5 million and $5.7 million, respectively. The increase in loss was primarily attributed to $1.0 million increase in other research and development expense, and $0.9 million increase in general and administrative expenses, partially offset by $1.0 million decrease in research and development expense incurred in connection with the license acquired.
- For the year ended December 31, 2020 and 2019, other (expense) income was approximately $(5.8) million and $1.5 million, respectively. The increase in other expense was primarily attributed to a $8.2 million decrease in change in fair value of investment in Hoth, due to the decrease in Hoth’s common stock price for the year ended December 31, 2020, and partially offset by $1.0 million increase in gains on marketable securities.
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Bad
|
|
New words:
accelerated, annum, anticancer, antigen, arrangement, ASC, award, Bander, bifurcation, brain, chapter, check, claim, committee, compensation, confusion, consideration, Convergent, Cornell, decision, delivered, depression, dysfunction, electronically, embedded, emerging, Employer, enterprise, equal, filer, Florida, forward, host, improve, instrument, Interactive, invented, IP, irrevocable, jurisdiction, mark, Master, mature, maturity, Medicine, membrane, MLA, Moving, nausea, Neil, neural, neuroinflammation, NNPT, noncurrent, nonrefundable, Nuta, original, overallotment, Page, pain, par, Parma, peptide, posted, preservation, priority, Professor, promissory, provisional, PRRT, psilocybin, PSMA, qualitative, quantitative, radionuclide, receptor, representative, revised, running, separate, separately, shell, Silo, simplify, Simplifying, SMS, SMSI, SPAII, sublicensable, Subsidiary, Title, type, underwriter, underwriting, underwritten, unpaid, Unregistered, unvested, Urologic, vested, Wainwright, Washington, Weill
Removed:
ability, acceptable, accounted, accretion, acquiring, add, administration, agent, applicable, approval, approved, assessment, atopic, attributable, August, average, Basic, begin, beneficial, bid, BioPharma, biopharmaceutical, blockchain, calculation, calendar, carrying, CBM, Certificate, clinical, clinically, close, closing, combat, commence, communication, compliance, comply, comprise, computed, conduct, conform, consecutive, consist, consuming, continued, continuing, credit, DatChat, dated, declared, deemed, deficiency, designate, Designation, develop, digital, dilutive, direct, distribute, distribution, dividing, documented, eczema, efficacy, enacted, encrypted, enter, entity, eventually, exceed, execute, expansion, expensive, experience, expire, extent, extinguishment, failed, FDA, feature, federal, fee, final, focusing, foregoing, fourth, Framework, funding, governmental, hierarchy, holder, iii, immaterial, implemented, increasing, incremental, IND, informing, infrastructure, inhibit, internet, issuable, June, letter, life, limit, listing, longer, made, maintenance, manufacturing, Marketplace, meant, medical, meet, minimum, model, modify, monetization, monetizing, monitoring, mouse, movement, notice, offered, office, ownership, party, percentage, performed, personal, pharmaceutical, placement, plan, pricing, primary, privacy, privately, proposed, prosecuted, prosecution, publicly, record, reduce, regain, regulatory, relevant, rely, remove, replication, require, requirement, review, reviewed, safety, schedule, scope, Secretary, secure, security, seek, shareholder, spread, stage, strategic, successful, successfully, suffering, sufficient, system, terminated, termination, test, testing, timeline, trademark, transgenic, transitioning, treasury, treat, trial, unmet, update, volatility, VStock, weighted
Financial reports
10-Q
2021 Q1
Quarterly report
10 May 21
10-K
2020 FY
Annual report
25 Mar 21
10-Q
2020 Q3
Quarterly report
13 Nov 20
10-Q
2020 Q2
Quarterly report
6 Aug 20
10-Q
2020 Q1
Quarterly report
14 May 20
10-K
2019 FY
Annual report
2 Feb 20
10-Q
2019 Q3
Quarterly report
12 Nov 19
10-Q
2019 Q2
Quarterly report
13 Aug 19
10-Q
2019 Q1
Quarterly report
15 May 19
10-K
2018 FY
Annual report
11 Mar 19
Current reports
8-K
Other Events
19 Jul 21
8-K
Departure of Directors or Certain Officers
2 Jul 21
8-K
Other Events
23 Jun 21
8-K
Other Events
10 Jun 21
8-K
Other Events
13 May 21
8-K
Other Events
3 May 21
8-K
Entry into a Material Definitive Agreement
16 Apr 21
8-K
Changes in Registrant's Certifying Accountant
13 Apr 21
8-K
Regulation FD Disclosure
5 Mar 21
8-K
AIkido Pharma Inc. Increases Previously Announced Bought Deal Offering of Common Stock to $75 Million
18 Feb 21
Registration and prospectus
RW
Registration withdrawal request
21 Apr 21
424B5
Prospectus supplement for primary offering
18 Feb 21
424B5
Prospectus supplement for primary offering
15 Feb 21
S-1/A
IPO registration (amended)
26 Aug 20
S-1
IPO registration
17 Aug 20
S-3/A
Shelf registration (amended)
12 Jun 20
S-3/A
Shelf registration (amended)
8 Jun 20
S-3
Shelf registration
11 May 20
424B5
Prospectus supplement for primary offering
15 Apr 20
424B5
Prospectus supplement for primary offering
10 Mar 20
Proxies
DEFA14A
Additional proxy soliciting materials
4 Dec 20
DEFA14A
Additional proxy soliciting materials
25 Nov 20
DEF 14A
Definitive proxy
5 Oct 20
PRE 14A
Preliminary proxy
23 Sep 20
DEFA14A
Additional proxy soliciting materials
23 Aug 19
DEFA14A
Additional proxy soliciting materials
19 Aug 19
DEFA14A
Additional proxy soliciting materials
11 Aug 19
DEF 14A
Definitive proxy
24 Jul 19
DEFA14A
Additional proxy soliciting materials
19 Jun 19
PRE 14A
Preliminary proxy
18 Jun 19
Other
EFFECT
Notice of effectiveness
19 Jun 20
CORRESP
Correspondence with SEC
15 Jun 20
CORRESP
Correspondence with SEC
11 Jun 20
UPLOAD
Letter from SEC
10 Jun 20
CORRESP
Correspondence with SEC
7 Jun 20
UPLOAD
Letter from SEC
21 May 20
EFFECT
Notice of effectiveness
4 Mar 20
CORRESP
Correspondence with SEC
1 Mar 20
CORRESP
Correspondence with SEC
1 Mar 20
CORRESP
Correspondence with SEC
27 Feb 20
Ownership
4
AIkido Pharma / Anthony Hayes ownership change
4 May 21
4
AIkido Pharma / Anthony Hayes ownership change
30 Apr 21
4
AIkido Pharma / Anthony Hayes ownership change
23 Apr 21
3
AIkido Pharma / Kyle Michael Wool ownership change
16 Apr 21
SC 13D
AIkido Pharma / FiveT Investment Management ownership change
25 Feb 21
SC 13G
AIkido Pharma / CVI Investments ownership change
25 Feb 21
SC 13G
Hoth Therapeutics / AIkido Pharma ownership change
16 Feb 21
5
Annual statement of changes in insider ownership
16 Feb 21
SC 13G/A
AIkido Pharma / CVI Investments ownership change
16 Feb 21
4
Aikido Pharma / Paul LeMire ownership change
8 Jan 21
Reddit threads
News Out Today! Under the radar, low float with patented psilocybin treatments. Silo Pharma (OTCQB: SILO)
27 Jul 21
THE LOUNGE/DAILY PLAYS July 21, 2021
20 Jul 21
Hot Sector, a Psychedelic Biopharma Enterprise with a Focus Toward New Science, Shareholder Value, Patented Tech on Psilocybin and Recently Announced Plans to Up-list to the NASDAQ
14 Jul 21
Hot Sector and Opportunity in a Psychedelic Biopharma Enterprise with a Focus Toward New Science, Shareholder Value and Recently Announced Plans to Up-list to the NASDAQ
11 Jul 21
What Are Your Moves Tomorrow, June 04, 2021
3 Jun 21
Which one of these Stocks Will close with the highest gain Friday?
3 Jun 21
THE LOUNGE/DAILY PLAYS June 02, 2021
1 Jun 21
Daily Plays - May 27, 2021
27 May 21
Daily Plays - May 24, 2021
24 May 21
THE LOUNGE: thoughts, noob stuff, low effort, brokers, zero DD, non pennies - May 22, 2021
21 May 21